CUE HEALTH INC (HLTH)
US2297901009 - Common Stock
HLTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. HLTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, HLTH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
HLTH had negative earnings in the past year.
In the past year HLTH has reported a negative cash flow from operations.
HLTH had negative earnings in 4 of the past 5 years.
In the past 5 years HLTH reported 4 times negative operating cash flow.
1.2 Ratios
HLTH's Return On Assets of -109.92% is on the low side compared to the rest of the industry. HLTH is outperformed by 81.68% of its industry peers.
With a Return On Equity value of -149.25%, HLTH is not doing good in the industry: 76.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.92% | ||
| ROE | -149.25% | ||
| ROIC | N/A |
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for HLTH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
HLTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLTH has been increased compared to 1 year ago.
HLTH has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -4.83, we must say that HLTH is in the distress zone and has some risk of bankruptcy.
HLTH's Altman-Z score of -4.83 is on the low side compared to the rest of the industry. HLTH is outperformed by 68.59% of its industry peers.
There is no outstanding debt for HLTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.83 |
ROIC/WACCN/A
WACC9.06%
2.3 Liquidity
HLTH has a Current Ratio of 2.54. This indicates that HLTH is financially healthy and has no problem in meeting its short term obligations.
HLTH has a Current ratio (2.54) which is in line with its industry peers.
A Quick Ratio of 2.22 indicates that HLTH has no problem at all paying its short term obligations.
HLTH has a Quick ratio (2.22) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.22 |
3. Growth
3.1 Past
The earnings per share for HLTH have decreased strongly by -153.47% in the last year.
HLTH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -85.32%.
Measured over the past years, HLTH shows a very strong growth in Revenue. The Revenue has been growing by 45.56% on average per year.
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%
3.2 Future
The Earnings Per Share is expected to grow by 17.29% on average over the next years. This is quite good.
Based on estimates for the next years, HLTH will show a very strong growth in Revenue. The Revenue will grow by 52.69% on average per year.
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HLTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLTH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HLTH's earnings are expected to grow with 24.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.95%
EPS Next 3Y24.25%
5. Dividend
5.1 Amount
HLTH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CUE HEALTH INC
NASDAQ:HLTH (6/5/2024, 8:00:01 PM)
After market: 0.0489 +0.01 (+12.67%)0.0434
-0.02 (-29.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners1.03%
Inst Owner Change0%
Ins Owners29.79%
Ins Owner Change0%
Market Cap6.90M
Analysts43.33
Price Target0.51 (1075.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.92%
Min EPS beat(2)-120.16%
Max EPS beat(2)6.32%
EPS beat(4)1
Avg EPS beat(4)-29.65%
Min EPS beat(4)-120.16%
Max EPS beat(4)6.32%
EPS beat(8)5
Avg EPS beat(8)14.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.53%
Min Revenue beat(2)2.82%
Max Revenue beat(2)4.24%
Revenue beat(4)3
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-27.41%
Max Revenue beat(4)5.48%
Revenue beat(8)7
Avg Revenue beat(8)33.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-52.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-38.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.03 | ||
| P/tB | 0.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.45
BVpS1.57
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -109.92% | ||
| ROE | -149.25% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 35.18% | ||
| Cap/Sales | 27.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.22 | ||
| Altman-Z | -4.83 |
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)177.13%
Cap/Depr(5y)371.33%
Cap/Sales(3y)19.89%
Cap/Sales(5y)88.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%
EBIT growth 1Y-45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.74%
EBIT Next 3Y13.08%
EBIT Next 5Y20.63%
FCF growth 1Y9.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.13%
OCF growth 3YN/A
OCF growth 5YN/A